Joel Isaacson & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Joel Isaacson & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-351	Closed	-$21K	–	538
2016 Q4	$21K	Buy	351 +1	+0.3%	+$62	﹤0.01%	425
2016 Q3	$23K	Hold	350	–	–	﹤0.01%	444
2016 Q2	$19K	Buy	350 +50	+17%	+$2.74K	﹤0.01%	472
2016 Q1	$15K	Buy	+300	New	+$15.6K	﹤0.01%	530

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Joel Isaacson & Co's XBI Position: Q1 2017 in Review

Joel Isaacson & Co sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 351 shares — an estimated $21K sold.

Joel Isaacson & Co first reported a position in XBI in Q1 2016 and held it in 4 quarters. The position peaked at $23K in Q3 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

Joel Isaacson & Co reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 351 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $21K.
Joel Isaacson & Co first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and held it in 4 quarters.
Joel Isaacson & Co's State Street SPDR S&P Biotech ETF position peaked at $23K in Q3 2016.
292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.